<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Forum Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Open Forum Infect Dis</journal-id><journal-id journal-id-type="publisher-id">ofid</journal-id><journal-title-group><journal-title>Open Forum Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2328-8957</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5631465</article-id><article-id pub-id-type="doi">10.1093/ofid/ofx163.718</article-id><article-id pub-id-type="publisher-id">ofx163.718</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Poster Abstract</subject></subj-group></subj-group></article-categories><title-group><article-title>Phase 1 Clinical Trial of a Replication-Defective Human Cytomegalovirus (CMV) Vaccine</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Adler</surname><given-names>Stuart</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Lewis</surname><given-names>Nicole</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Conlon</surname><given-names>Anthony</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Christiansen</surname><given-names>Mark</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Al-Ibrahim</surname><given-names>Mohamed S</given-names></name><degrees>MB, ChB</degrees><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Rupp</surname><given-names>Richard</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0005">5</xref></contrib><contrib contrib-type="author"><name><surname>Fu</surname><given-names>Tong Ming</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Bautista</surname><given-names>Oliver</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Tang</surname><given-names>Huaping</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Culp</surname><given-names>Timothy</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Das</surname><given-names>Rituparna</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Beck</surname><given-names>Karen</given-names></name><degrees>RN, BSN</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Tamms</surname><given-names>Gretchen</given-names></name><degrees>BS</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Musey</surname><given-names>Luwy</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib></contrib-group><aff id="AF0001">
<label>1</label>
<institution>CMV Research Foundation</institution>, <addr-line>Richmond, VA</addr-line></aff><aff id="AF0002">
<label>2</label>
<institution>Merck &#x00026; Co., Inc.</institution>, <addr-line>Kenilworth, New Jersey</addr-line></aff><aff id="AF0003">
<label>3</label>
<institution>Diablo Clinical Research, Inc.</institution>, <addr-line>Walnut Creek, California</addr-line></aff><aff id="AF0004">
<label>4</label>
<institution>SNBL Clinical Pharmacology Center, Inc.</institution>, <addr-line>Baltimore, MD</addr-line></aff><aff id="AF0005">
<label>5</label>
<institution>University of Texas Medical Branch at Galveston</institution>, <addr-line>Galveston, TX</addr-line></aff><author-notes><fn id="fn-0001"><p>
<bold>Session:</bold> 138. Adult Immunization - Miscellaneous</p><p>
<italic>Friday, October 6, 2017: 12:30 PM</italic>
</p></fn></author-notes><pub-date pub-type="collection"><season>Fall</season><year>2017</year></pub-date><pub-date pub-type="epub" iso-8601-date="2017-10-04"><day>04</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>04</day><month>10</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>4</volume><issue>Suppl 1</issue><issue-title>ID Week 2017 Abstracts</issue-title><fpage>S308</fpage><lpage>S309</lpage><permissions><copyright-statement>&#x000a9; The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</copyright-statement><copyright-year>2017</copyright-year><license license-type="cc-by-nc-nd" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xlink:href="ofx163.718.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>Congenital CMV remains an unmet medical need worldwide. Naturally acquired CMV immunity in women prior to pregnancy has been shown effective in reducing maternal-fetal transmission. V160 is engineered as a replication-defective CMV, and its replication in culture is controlled by a synthetic chemical. V160 can&#x02019;t replicate in humans but it maintains all virological properties for presentation of viral antigens, including gH/gL/pUL128-131 pentameric complex, important for potent neutralizing antibodies (NABs).</p></sec><sec id="s2"><title>Methods</title><p>Approximately 190 CMV seronegative and seropositive adults at study entry received 3 doses of V160 or placebo administered via intramuscular (IM) or intradermal (ID) route on Day 1, Month 1, and Month 6.&#x000a0;Four antigen levels (10, 30, 100, and 250 units per dose) formulated with or without aluminum phosphate adjuvant were evaluated. In each vaccination group, approximately 10 and 4 subjects received study vaccine and placebo, respectively. Injection site and systemic adverse events (AEs) were collected for 14&#x000a0;days after each vaccination. Serious AEs (SAEs) were assessed up to Month 18. Viral shedding (urine and saliva) were monitored up to Month 12. CMV-specific NABs and cell-mediated immune responses (CMI) were measured prior and 1&#x000a0;month after each vaccination, and at Months 12 and&#x000a0;18.</p></sec><sec id="s3"><title>Results</title><p>During the study, no serious AEs were reported and only one CMV seropositive subject had non-vaccine type viral shedding. In both seronegative and seropositive cohorts, proportion of subjects who reported injection site AEs was higher in V160 recipients than placebo controls. Proportion of subjects who reported systemic AEs was comparable across V160 doses/formulations and placebo. In the CMV seronegative cohort, immune responses increased with incremental dosing. More importantly, recipients of V160 from several dose levels mounted NAB and CMI responses at 1&#x000a0;month post dose 3 (PD3) that were comparable to baseline levels measured in seropositive subjects.</p></sec><sec id="s4"><title>Conclusion</title><p>V160 had acceptable safety profile across all dose levels and formulations studied; Vaccine was immunogenic and elicited NAB and CMI responses at 1&#x000a0;month PD3 that were comparable to natural CMV infection.</p></sec><sec id="s5"><title>Disclosures</title><p>
<bold>S. Adler</bold>, Merck: Investigator, Research grant. <bold>N. Lewis</bold>, Merck: Employee, Salary. <bold>A. Conlon</bold>, Merck: Employee, Salary. <bold>M. Christiansen</bold>, Merck: Investigator, Research grant. <bold>M. S.&#x000a0;Al-Ibrahim</bold>, Merck: Investigator, Research grant <bold>R. Rupp</bold>, Merck: Investigator, Research grant. <bold>T. M.&#x000a0;Fu</bold>, Merck: Employee, Salary. <bold>O. Bautista</bold>, Merck: Employee, Salary. <bold>H. Tang</bold>, Merck: Employee, Salary.<bold>T. Culp</bold>, Merck: Employee, Salary. <bold>R. Das</bold>, Merck: Employee, Salary. <bold>K. Beck</bold>, Merck: Employee, Salary. <bold>G. Tamms</bold>, Merck: Employee, Salary. <bold>L. Musey</bold>, Meck: Employee, Salary.</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>